{"id":45943,"date":"2025-11-05T23:21:12","date_gmt":"2025-11-05T15:21:12","guid":{"rendered":"https:\/\/flcube.com\/?p=45943"},"modified":"2025-11-05T23:21:13","modified_gmt":"2025-11-05T15:21:13","slug":"prelude-therapeutics-revamps-pipeline-incyte-option-on-jak2v617f-kat6a-degrader-takes-center-stage-smarca2-paused","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45943","title":{"rendered":"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused"},"content":{"rendered":"\n<p>Prelude Therapeutics (<a href=\"https:\/\/www.google.com\/finance\/quote\/PRLD:NASDAQ\">NASDAQ: PRLD<\/a>) unveiled a suite of strategic shifts: it signed an option deal with Incyte for its <strong>JAK2V617F<\/strong> mutant selective inhibitor, set the <strong>KAT6A selective degrader<\/strong> as a top priority for ER\u207a breast cancer, and halted its <strong>SMARCA2<\/strong> degrader program to re\u2011focus resources.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-highlights\">Strategic Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Update<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Option Agreement<\/strong><\/td><td>Incyte secured an exclusive option to acquire Prelude\u2019s undisclosed <strong>JAK2V617F<\/strong> mutant\u2011selective inhibitor program for myeloproliferative neoplasms (MPNs).<\/td><\/tr><tr><td><strong>Pipeline Re\u2011prioritisation<\/strong><\/td><td>Prelude promotes its <strong>first\u2011in\u2011class KAT6A selective degrader<\/strong> for ER\u207a breast cancer to 2026 clinical read\u2011iness.<\/td><\/tr><tr><td><strong>Program Pause<\/strong><\/td><td>Clinical development of the <strong>SMARCA2 degrader<\/strong> program is paused pending resource reallocation.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-incyte-s-exclusive-option-on-jak2v617f\">Incyte\u2019s Exclusive Option on JAK2V617F<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transaction Details<\/strong> \u2013 Incyte pays an upfront fee and invests equity in Prelude, with future milestone payments, royalties, and downstream terms contingent on development progress.<\/li>\n\n\n\n<li><strong>Ownership Structure<\/strong> \u2013 Prelude retains all assets and development rights until the option is exercised; post\u2011exercise, Incyte will spearhead global development and commercialization.<\/li>\n\n\n\n<li><strong>Strategic Match<\/strong> \u2013 The JAK2V617F JH\u2082 mutant is a highly sought\u2011after target in MPNs, positioning Incyte to expand its oncology pipeline.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-kat6a-degrader-a-first-in-class-innovation\">KAT6A Degrader \u2013 A First\u2011In\u2011Class Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Logic<\/strong> \u2013 Selective degradation of KAT6A offers a differentiated therapeutic window versus the broader KAT6A\/B inhibitors that are in clinical trials.<\/li>\n\n\n\n<li><strong>Clinical Roadmap<\/strong> \u2013 Prelude plans to launch phase\u202fI\/II studies in <strong>2026<\/strong>, aiming for proof\u2011of\u2011concept data that could reveal superior efficacy or safety compared to non\u2011selective agents.<\/li>\n\n\n\n<li><strong>Commercial Imperative<\/strong> \u2013 ER\u207a breast cancer remains a high\u2011need area; a selective degrader could capture significant market differentiation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-smarca2-program-pause\">SMARCA2 Program Pause<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Data\u2011Driven Decision<\/strong> \u2013 Comprehensive review of current data indicated limited incremental benefit relative to resource commitment.<\/li>\n\n\n\n<li><strong>Capital Allocation<\/strong> \u2013 The pause reflects a strategic choice to funnel capital toward the more promising JAK2 and KAT6A pipelines, aligning with value\u2011inflection points.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-and-investor-implications\">Market and Investor Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Efficiency<\/strong> \u2013 Prelude\u2019s realignment signals disciplined stewardship of R&amp;D budgets, potentially easing investor concerns about dilution and burn.<\/li>\n\n\n\n<li><strong>Therapeutic Landscape<\/strong> \u2013 The JAK2V617F alliance strengthens Incyte\u2019s MPN offerings, while the KAT6A degrader adds a novel tool to the breast cancer armamentarium.<\/li>\n\n\n\n<li><strong>Stock Performance<\/strong> \u2013 The option deal adds upside potential for Prelude through equity upside and future royalties, while the pause removes a lower\u2011prioritised asset from the pipeline.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bottom-line\">Bottom Line<\/h2>\n\n\n\n<p>Prelude Therapeutics\u2019 November 2025 updates recalibrate its research portfolio: securing Incyte\u2019s option on a transformative <strong>JAK2V617F<\/strong> program, prioritising a cutting\u2011edge <strong>KAT6A degrader<\/strong> for ER\u207a breast cancer, and temporarily halting the <strong>SMARCA2<\/strong> degrader to optimise resource deployment. These moves sharpen Prelude\u2019s focus and enhance its attractiveness to investors seeking high\u2011impact oncology innovation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45945,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,4432,4431],"class_list":["post-45943","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-nasdaq-prld","tag-prelude-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal with Incyte for its JAK2V617F mutant selective inhibitor, set the KAT6A selective degrader as a top priority for ER\u207a breast cancer, and halted its SMARCA2 degrader program to re\u2011focus resources.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45943\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused\" \/>\n<meta property=\"og:description\" content=\"Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal with Incyte for its JAK2V617F mutant selective inhibitor, set the KAT6A selective degrader as a top priority for ER\u207a breast cancer, and halted its SMARCA2 degrader program to re\u2011focus resources.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45943\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T15:21:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T15:21:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0511.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused\",\"datePublished\":\"2025-11-05T15:21:12+00:00\",\"dateModified\":\"2025-11-05T15:21:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943\"},\"wordCount\":471,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0511.webp\",\"keywords\":[\"Cancer\",\"NASDAQ: PRLD\",\"Prelude Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45943#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45943\",\"name\":\"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0511.webp\",\"datePublished\":\"2025-11-05T15:21:12+00:00\",\"dateModified\":\"2025-11-05T15:21:13+00:00\",\"description\":\"Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal with Incyte for its JAK2V617F mutant selective inhibitor, set the KAT6A selective degrader as a top priority for ER\u207a breast cancer, and halted its SMARCA2 degrader program to re\u2011focus resources.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45943\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0511.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0511.webp\",\"width\":1080,\"height\":608,\"caption\":\"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45943#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused - Insight, China&#039;s Pharmaceutical Industry","description":"Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal with Incyte for its JAK2V617F mutant selective inhibitor, set the KAT6A selective degrader as a top priority for ER\u207a breast cancer, and halted its SMARCA2 degrader program to re\u2011focus resources.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45943","og_locale":"en_US","og_type":"article","og_title":"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused","og_description":"Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal with Incyte for its JAK2V617F mutant selective inhibitor, set the KAT6A selective degrader as a top priority for ER\u207a breast cancer, and halted its SMARCA2 degrader program to re\u2011focus resources.","og_url":"https:\/\/flcube.com\/?p=45943","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T15:21:12+00:00","article_modified_time":"2025-11-05T15:21:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0511.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45943#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45943"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused","datePublished":"2025-11-05T15:21:12+00:00","dateModified":"2025-11-05T15:21:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45943"},"wordCount":471,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45943#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0511.webp","keywords":["Cancer","NASDAQ: PRLD","Prelude Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45943#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45943","url":"https:\/\/flcube.com\/?p=45943","name":"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45943#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45943#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0511.webp","datePublished":"2025-11-05T15:21:12+00:00","dateModified":"2025-11-05T15:21:13+00:00","description":"Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal with Incyte for its JAK2V617F mutant selective inhibitor, set the KAT6A selective degrader as a top priority for ER\u207a breast cancer, and halted its SMARCA2 degrader program to re\u2011focus resources.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45943#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45943"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45943#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0511.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0511.webp","width":1080,"height":608,"caption":"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45943#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0511.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45943"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45943\/revisions"}],"predecessor-version":[{"id":45946,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45943\/revisions\/45946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45945"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}